MONMOUTH JUNCTION, N.J.,
July 31,
2024 /PRNewswire/ -- Creatv Bio, a Division of Creatv
MicroTech, Inc. (Creatv) announced that its Cancer Associated
Macrophage-Like (CAML) liquid biopsy biomarker has been included as
part of the pivotal Phase 3 trial of BriaCell Therapeutics
Corporation's lead clinical candidate, Bria-IMT in combination with
an immune checkpoint inhibitor in metastatic breast cancer.
This study is expected to enroll a total of 404 patients in two
arms – Bria-IMT in combination with an immune checkpoint inhibitor
versus treatment of physicians' choice in late-stage metastatic
breast cancer patients, with no approved alternative therapies
available (listed on ClinicalTrials.gov
as NCT06072612). Bria-IMT was awarded Fast Track status
by the U.S. Food and Drug Administration (FDA).
Blood samples are being provided to Creatv to analyze for the
presence of circulating tumor cells (CTCs), CAML subtyping, and to
monitor PD-L1 upregulation in patients. The samples are being taken
at baseline and at a designated time following the initial patient
treatment.
Creatv previously demonstrated that CAMLs can accurately
(i) predict a cancer's aggressiveness as well as multi-organ
metastasis, (ii) provide a universal companion diagnostics tool
using blood instead of tissue from patients, (iii) predict
treatment response within approximately 30 days of receiving a new
therapy in any solid tumor type, (iv) detect minimal residual
disease, and (v) cancer recurrence.
"The use of biomarkers like CAMLs holds great promise in helping
clinicians determine whether a patient is responding to a specific
therapy in a timely manner," remarked Dr. Cha-Mei Tang, President and CEO of Creatv Bio. "We
are looking forward to participating in this important trial with
BriaCell and are confident that as a result, this biomarker will
provide clinicians with a valuable tool to guide their treatment
choices for cancer patients."
About Creatv Bio
Creatv is a cancer screening and cancer diagnostics company
providing testing services to patients and to support drug
development from its CLIA/CAP laboratory in NJ. Creatv's scientists
were the first to publish CAMLs found in the blood of cancer
patients. Since this original publication in 2014, CAMLs have been
validated by dozens of independent groups worldwide. For a complete
listing of our journal publications and posters, please visit our
website at https://creatvbio.com/.
For more information contact:
|
Daniel
Adams,
|
|
Ron
Baker
|
|
|
Director of Clinical
R&D
|
|
Chief Business
Officer
|
|
|
dan@creatvmicrotech.com
|
|
ron@creatvmicrotech.com
|
|
|
732-783-7132
(office)
|
|
301-785-5185
(mobile)
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creatv-bio-announces-its-caml-biomarker-included-in-pivotal-phase-3-trial-in-metastatic-breast-cancer-302210235.html
SOURCE Creatv MicroTech, Inc.